Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany.
Monika Engelhardt, Gabriele Ihorst, Moushmi Singh...
https://pubmed.ncbi.nlm.nih.gov/33218965/Actively Recruiting
Led by iOMEDICO AG · Updated on 2026-07-13
2200
Participants Needed
1
Research Sites
104 weeks
Total Duration
This research aims to establish a national, prospective, longitudinal, multicenter cohort study in Germany to collect standardized data on patients with Multiple Myeloma. The study focuses on documenting patient characteristics, molecular diagnostics, treatments, and disease progression over time. The goal is to better understand treatment patterns and outcomes across different therapies for Multiple Myeloma, while also collecting patient-reported quality of life measures. Participants receive routine care as determined by their physicians based on individual needs without experimental interventions. The study tracks all systemic treatments, radiotherapies, surgeries, and disease outcomes for up to five years. A decentralized biobank is also established to support molecular testing and research alongside the registry. The study includes a satellite project evaluating health-related quality of life through patient questionnaires. During participation, data on patient conditions, prior treatments, and comorbidities are collected at enrollment. Follow-up data include treatment details, response to therapy, survival outcomes, and quality of life assessments over five years. Researchers use these data to analyze treatment sequences, disease course, and patient well-being. Participation involves routine monitoring without additional treatment procedures, and the total follow-up can last up to five years.
CONDITIONS
Myeloma Registry Platform (MYRIAM)
M
Martina Jänicke, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
iOMEDICO AG
Lead Sponsor
Deutsche Studiengruppe Multiples Myelom (DSMM)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 5 years
Participants receive routine care while data on treatments, disease progression, and quality of life are collected over time.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Monika Engelhardt, Gabriele Ihorst, Moushmi Singh...
https://pubmed.ncbi.nlm.nih.gov/33218965/iOMEDICO AG
Lead Sponsor
Deutsche Studiengruppe Multiples Myelom (DSMM)
Collaborating Sponsor